Pharming vs Xeris Biopharma
PHAR and XERS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PHAR and XERS compare
Xeris Biopharma grew revenue faster over the last twelve months (38.4% versus 26.6% for Pharming).
Pharming keeps more of each dollar of sales as profit, with a net margin of 0.76% compared with −1.8% at Xeris Biopharma.
Xeris Biopharma scores higher on the StockData Score (11 against 8 for Pharming), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PHAR | XERS |
|---|---|---|
| Size and price | ||
| Market cap | – | $3.0B |
| Share price | $13.40 | $16.52 |
| Change, 1 year | −23.6% | 114% |
| Change, 5 years | 55.5% | 628% |
| Beta (5Y) | 0.56 | 1.14 |
| Employees | 50K | 435 |
| StockData Score | ||
| Total score | 8 | 11 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 4 (better) |
| Performance score | 1 | 4 (better) |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 8.2× |
| P/B | – | 61.7× |
| EV/EBITDA | – | 63.9× |
| Fair value | – | $3.56 |
| Margin of safety | – | −364% |
| Growth | ||
| Revenue growth (TTM) | 26.6% | 38.4% (better) |
| Revenue growth, 5Y average | 12.1% | 70.2% (better) |
| EPS growth, 5Y average | −40.8% | – |
| Profitability | ||
| Gross margin | 87.9% (better) | 87.4% |
| Operating margin | 6.9% | 12.7% (better) |
| Net margin | 0.76% (better) | −1.8% |
| FCF margin | 14.3% | – |
| Return on equity | – | −27.1% |
| Return on invested capital | – | 31.5% |
| Financial health | ||
| Debt / equity | – | 3.89 |
| Net debt / EBITDA | – | 1.22 |
| Interest coverage | 132× (better) | 1.7× |
| Current ratio | 2.59 (better) | 2.15 |
| Altman Z-score | – | 4.22 |
| Piotroski F-score | 7 | 8 (better) |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.32% | 59.4% |
| Held by insiders | 0.00% | 5.2% |
| Insider net buying, 12 months | – | −$5.8M |
| Short interest, % of float | – | 5.2% |
Go deeper
- PHAR stock overview
- PHAR income statement
- PHAR valuation and score
- XERS stock overview
- XERS income statement
- XERS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.